RxDoctor Payments Data

Bryan Wilson, MD

Cardiovascular Disease · Charlotte, NCNPI 1922111905

Payments from drug & device makers

$35,547in general payments, 2019–2025

Across 39 payments — averaging $911.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$27K
  • Sanofi-aventis U.S. LLC$8K
  • Biotronik Inc.$155
  • Stryker$155
  • Novartis$22
  • E.r. Squibb & Sons, L.L.C.$18
  • plus $12 from 1 others

What the payments were for

  • Speaking & faculty fees$5,88869%
  • Travel & lodging$2,23226%
  • Food & beverage$3814%
  • Education$190%

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,547 in reported general payments places this provider in the 80th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$57,552
Medicare patients
230
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$143,498
XareltoRivaroxaban50$48,501
Repatha SureclickEvolocumab29$26,467
MultaqDronedarone Hcl11$23,188
BrilintaTicagrelor12$5,645
Metoprolol Succinate172$2,461
Atorvastatin Calcium209$1,863
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$1,291
Carvedilol106$969
Losartan Potassium91$932
Potassium Chloride68$834
Omeprazole46$756
ClopidogrelClopidogrel Bisulfate62$736
Pravastatin Sodium35$616
Lisinopril70$600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$8,127$23,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →